Novel therapeutic options for multiple sclerosis (Q38170129)

30 August 2017

Novel therapeutic options for multiple sclerosis (English)

1 reference

30 August 2017

0 references

2

Hans-Peter Hartung

1 reference

30 August 2017

François Curtin

1

1 reference

PubMed ID

24325127

30 August 2017

language of work or name

English

0 references

publication date

10 December 2013

1 reference

Expert Review of Clinical Pharmacology

30 August 2017

1 reference

30 August 2017

7

1 reference

30 August 2017

1

1 reference

30 August 2017

91-104

1 reference

Multiple sclerosis: a complicated picture of autoimmunity.

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

The immunopathology of multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Recent developments in multiple sclerosis therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Recent insights into the mechanism of action of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Comment: assessing humoral immunocompetence after alemtuzumab treatment in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

The role of natural killer cells in multiple sclerosis and their therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Antibodies to watch in 2013: Mid-year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Cytokines and effector T cell subsets causing autoimmune CNS disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Effect of IL-17A blockade with secukinumab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Clinical prognostic factors in multiple sclerosis: a natural history review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Prognosis-modifying therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Treating multiple sclerosis with monoclonal antibodies: a 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Managing the risks of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.865517

10.1586/17512433.2014.865517

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24325127